Positive Buy Rating for Lineage Cell Therapeutics Driven by Clinical Progress and Financial Stability

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Lineage Therap, with a price target of $3.00.

Michael Okunewitch has given his Buy rating due to a combination of factors including Lineage Cell Therapeutics’ promising progress in its clinical studies and its solid financial position. The company reported a manageable operating loss and maintains a substantial cash reserve, which is expected to support its operations into the second quarter of 2027.
Additionally, the ongoing DOSED study for OPC1 has shown encouraging safety results, with no significant safety concerns reported 60 days after treatment of the first patient. The potential approval of a significant grant from the California Institute for Regenerative Medicine could further bolster the company’s financial resources and support the expansion of its clinical programs. Furthermore, the company’s pipeline expansion into new therapeutic areas, such as its islet cell therapy program for Type 1 diabetes, indicates a strategic focus on growth and innovation. These factors collectively contribute to the positive outlook and Buy rating for Lineage Therap’s stock.

In another report released yesterday, B. Riley Securities also maintained a Buy rating on the stock with a $3.00 price target.